8-K: Tempest Therapeutics Options In Vivo CAR-T Platform

Tempest Therapeutics secures an exclusive option to license Hebei Senlang Biotechnology's CD7-targeted lentiviral in vivo CAR-T platform, complementing its existing technology and potentially expanding its pipeline.

Summary

• Tempest Therapeutics has entered into an exclusive option and license agreement with Hebei Senlang Biotechnology Co., Ltd. (Senlang).
• This agreement grants Tempest an option to license Senlang's CD7-targeted lentiviral vector platform and a portfolio of in vivo CAR-T product candidates.
• The portfolio includes a BCMA/GPRC5D dual-targeting in vivo CAR-T candidate currently in Phase 1 dose escalation for relapsed/refractory multiple myeloma.
• The option, exercisable within four months, requires an approximate $447,000 option exercise fee if exercised.
• If the license is exercised, Tempest would be obligated to pay nomination fees, escalating annual maintenance fees ($10M-$14M over three years), a 6% royalty on net sales, and a share of sublicense revenue.
• Tempest must commit to using commercially reasonable efforts to develop and commercialize at least one Licensed Product and meet specified milestones.
• The agreement also includes rights of first negotiation for Greater China rights and customary termination provisions.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating strategic expansion and potential for pipeline growth, though the financial commitments and option nature introduce some uncertainty.

Positives

• Secures an exclusive option to a complementary in vivo CAR-T platform (lentiviral vector) that differs from Tempest's existing LNP platform.
• The licensed technology targets CD7-positive T cells and NK cells, enabling in vivo generation of CAR-T and CAR-NK cells, potentially avoiding complex ex vivo manufacturing.
• The lead candidate in Senlang's portfolio is a BCMA/GPRC5D dual-targeting in vivo CAR-T therapy currently in Phase 1 for relapsed/refractory multiple myeloma.
• Early clinical observations from the Phase 1 trial show in vivo CAR-T generation and expansion at the highest evaluable dose, with an initial safety profile supporting continued dose escalation.
• No Grade 3 or higher cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome were observed as of August 25, 2026.
• The dual-targeting approach may offer broader malignant plasma-cell coverage and reduce tumor escape potential.
• The agreement expands Tempest's potential immune reset portfolio across hematologic malignancies and autoimmune diseases.

Negatives

• The agreement is an option, not a definitive license, meaning Tempest may not proceed with the full commitment.
• Exercising the option incurs significant financial obligations, including an option exercise fee, nomination fees, escalating annual maintenance fees ($10M-$14M over three years), royalties, and sublicense revenue sharing.
• Tempest is required to commit to using commercially reasonable efforts to develop and commercialize at least one Licensed Product and meet specified milestones.
• The lentiviral platform is designed for durable CAR-cell generation, which may present different safety considerations compared to the transient expression from the LNP platform.

Risks

• The need for additional capital to fund planned programs and operations, and to continue operating as a going concern.
• Unexpected safety or efficacy data observed during preclinical or clinical trials.
• The possibility that results from prior clinical trials and preclinical studies may not be predictive of future results.
• Clinical trial site activation or enrollment rates that are lower than expected.
• Loss of key personnel.
• Changes in expected or existing competition.
• Changes in the regulatory environment.
• Volatility and uncertainty in the capital markets for biotechnology companies.

Future Outlook

Tempest Therapeutics has an exclusive option to license Senlang's CD7-targeted lentiviral in vivo CAR-T platform. If exercised, this would complement Tempest's existing LNP platform, providing two distinct approaches to in vivo CAR-T generation. The lead candidate, a BCMA/GPRC5D dual-targeting therapy, is in Phase 1 for multiple myeloma, with early data showing in vivo CAR-T generation and expansion. Tempest expects to provide additional information as clinical data matures.

Management Comments

• "This agreement represents an important step in building Tempest as a multi-platform in vivo CAR-T company focused on immune reset for oncology and autoimmune indications."
• "Upon exercise of the option, the CD7-targeted lentiviral platform would complement our targeted LNP platform, providing two distinct approaches to generating CAR-T cells directly within patients."
• "The lead program is currently in clinical development and has demonstrated in vivo CAR-T generation and expansion, providing encouraging early clinical support."
• "Together, our targeted LNP and targeted lentiviral vector platforms are intended to support a broad portfolio of immune reset therapies."
• "The LNP platform offers a potentially repeatable approach to transient CAR expression, while the lentiviral platform is designed to support durable CAR-cell generation."
• "These complementary capabilities provide Tempest with the flexibility to match the delivery approach to the biology and treatment requirements of different cancers and autoimmune diseases."

Industry Context

StockSavvy.ai notes that this move by Tempest Therapeutics aligns with the broader industry trend of exploring diverse delivery mechanisms for CAR-T therapies, particularly focusing on 'in vivo' approaches to simplify manufacturing and potentially broaden patient access. The acquisition of an option for a lentiviral platform complements their existing LNP technology, positioning them with multiple modalities to address various indications in oncology and autoimmune diseases.

Comparison to Industry Standards

• The development of in vivo CAR-T therapies is a cutting-edge area within the biotechnology sector, aiming to overcome the manufacturing complexities and costs associated with traditional ex vivo CAR-T therapies.
• Companies like Caribou Biosciences and Precision BioSciences are also developing in vivo gene editing and cell therapy approaches, though often with different vector systems or targets.
• The dual-targeting strategy (BCMA/GPRC5D) is a recognized approach in multiple myeloma, with other companies like Bristol Myers Squibb and AbbVie exploring similar multi-targeting CAR-T constructs for enhanced efficacy and resistance mitigation.

Stakeholder Impact

• Shareholders: Potential for pipeline expansion and future growth, but also increased financial obligations if the option is exercised.
• Patients: Potential for new therapeutic options for relapsed/refractory multiple myeloma and other hematologic malignancies or autoimmune diseases, with a potentially simplified treatment process.
• Creditors: The company's ongoing need for capital and potential future financial commitments could impact its financial stability.

Next Steps

• Tempest Therapeutics will evaluate the Phase 1 results and the broader product portfolio during the option period.
• Tempest expects to provide additional information regarding the program as the clinical data mature.
• If the option is exercised, Tempest will proceed with licensing Senlang's CD7-targeted lentiviral vector platform and associated product candidates.
• Tempest will continue dose escalation in the Phase 1 study for the BCMA/GPRC5D dual-targeting in vivo CAR-T candidate.

Key Dates

Recommendation

The filing details a strategic option agreement that could significantly expand Tempest's pipeline with a complementary in vivo CAR-T technology. The early positive clinical signals for the lead candidate are encouraging. However, the significant financial commitments required to exercise the option and the inherent risks in clinical development and biotechnology financing warrant a 'hold' recommendation until further clarity on option exercise and clinical progression is available.

Keywords

in vivo CAR-T, lentiviral vector, CD7, Tempest Therapeutics, Hebei Senlang Biotechnology, multiple myeloma, BCMA, GPRC5D